Supplementary materials for "The Benefit of Taxane-Based Therapies Over Fluoropyrimidine Plus Platinum (FP) in the Treatment of Esophageal Cancer: A meta-analysis of clinical studies".

<b>Table S1</b> Quality scores of cohort studies. <b>Table S2</b> Comparisons of all outcomes in curative effects. <b>Table S3</b> Comparisons of grade 3/4 adverse events.<b>Figure S1</b> A: Quality assessment of cohort studies; B: Risk of bias graph for randomized controlled trails (RCTs); C: Risk of bias summary for RCTs.<b>Figure S2</b> Funnel plots of Begg’s and Egger’s tests. A: Begg’s test for pathological complete response (pCR) in the subgroup of neoadjuvant chemoradiotherapy (NACRT); B: Egger’s test for pCR in the subgroup of NACRT.<b>Figure S3 </b>Analyses of side effects between taxane-based neoadjuvant chemotherapy (NACT) and fluoropyrimidine plus platinum (FP) based NACT in esophageal cancer (EC). A: grade 3/4 anemia; B: grade 3/4 leukopenia; C: grade 3/4 neutropenia; D: grade 3/4 thrombocytopenia; E: grade 3/4 anorexia; F: grade 3/4 nausea; G: grade 3/4 vomiting; H: grade 3/4 diarrhea.<b></b> <b>Figure S4 </b>Analyses of side effects between taxane-based definitive chemoradiotherapy (dCRT) and FP based dCRT in EC. A: grade 3/4 anemia; B: grade 3/4 leukopenia; C: grade 3/4 neutropenia; D: grade 3/4 thrombocytopenia; E: grade 3/4 anorexia; F: grade 3/4 nausea; G: grade 3/4 vomiting; H: grade 3/4 diarrhea; I: grade 3/4 esophagitis; J: grade 3/4 pneumonia.<b></b>